NEW YORK, NY— July 17, 2017 — Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 shares of common stock has been priced at $6.00 per share. Total gross proceeds from the offering will be $7,071,192.
The shares began trading on July 12, 2017 on the NASDAQ Capital Market under the ticker symbol “CODX.” The underwriters have a 45-day option to purchase up to 176,780 additional shares of common stock from Co-Diagnostics to cover over-allotments, if any. The Company intends to use the net proceeds for the development of tests, expansion of laboratory facilities, in-field test performance evaluation and validation, regulatory filings for diagnostic tests, and for working capital and general corporate purposes.
WallachBeth Capital LLC acted as co-book-running manager for the offering.
Co-Diagnostics’ registration statement relating to these securities was declared effective as of July 11, 2017 by the U.S. Securities and Exchange Commission.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. (“Company,” or “CDI,”), a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.
About WallachBeth Capital LLC
WallachBeth Capital is a leading provider of institutional execution services, offering clients a full spectrum of solutions to help them navigate increasingly complex markets.
The firm’s expertise includes capital markets, ETF and equity trading, and derivatives. Operating on a fully disclosed, agency-only basis, the firm is committed to facilitating all client needs with transparency and integrity. The firm’s website is located at www.wallachbeth.com.
For media inquiries: